Macro● Neutral
Biocon Chair Sees US Generics Tariffs as Negotiation Tactic
Biocon's chair says US generics tariff plan is a negotiation move, not a real threat. Company waits while exploring US partnerships for insulin and biologics.
Continue with
Biocon is holding off on any strategic response to proposed US tariffs on generic drugs, with executive chairperson Kiran Mazumdar-Shaw calling the plan a negotiation tactic rather than a policy that will take effect. Tariffs would clash with Washington's stated goal of lowering healthcare costs, she told Mint in an interview, describing the proposal as "more like a negotiating threat and less of a real threat."
"I think we will wait and watch, and we don't believe that this is going to be carried through," Shaw said.
The company, one of the world's largest biosimilar manufacturers, has already expanded US manufacturing capacity and is open to further local production through partnerships, not necessarily wholly owned plants. "You can partner, you can outsource... what is the right balance is what we need to look at," she said. Shaw pointed to a planned insulin fill-and-finish partnership and other opportunities via contract research arm Syngene International.